VIRX OTC
Viracta Therapeutics, Inc.
1W: +0.0%
1M: +0.0%
3M: +0.0%
1Y: -95.9%
3Y: -99.4%
5Y: -99.8%
$0.01
Last traded 2025-12-30 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$492K
-134.3% ▼
Operating Income
-$51M
-0.2% ▼
Net Income
-$51M
-2.6% ▼
EPS (Diluted)
$-1.32
+0.0% ▲
EBITDA
-$47M
+3.2% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $2M | $120K | $0 | $0 | $0 |
| YoY Growth | +774.7% | -94.2% | -100.0% | +0.0% | +0.0% |
| Cost of Revenue | $0 | $32K | $178K | $210K | $492K |
| Gross Profit | $2M | $88K | -$178K | -$210K | -$492K |
| Gross Margin | 100.0% | 73.3% | — | — | — |
| R&D Expenses | $15M | $13M | $24M | $26M | $33M |
| SG&A Expenses | $10M | $5M | $15M | $24M | $17M |
| Operating Expenses | $25M | $19M | $26M | $51M | $51M |
| Operating Income | -$23M | -$19M | $63M | -$51M | -$51M |
| Operating Margin | -1123.4% | -15679.2% | — | — | — |
| Interest Expense | $514K | $216K | $491K | $577K | $4M |
| Income Before Tax | -$23M | -$19M | -$115M | -$49M | -$51M |
| Tax Expense | $0 | $182K | $88M | $577K | $0 |
| Net Income | -$23M | -$19M | -$203M | -$50M | -$51M |
| Net Margin | -1125.4% | -15999.2% | — | — | — |
| EPS (Diluted) | $-0.97 | $-0.52 | $-6.37 | $-1.32 | $-1.32 |
| EBITDA | -$23M | -$19M | -$114M | -$48M | -$47M |
| Shares Outstanding | 24M | 37M | 32M | 38M | 39M |